Journal article · 2010 · Open access

Quetiapine versus other atypical antipsychotics for schizophrenia

Katja Komossa, Christine Rummel‐Kluge, Franziska Schmid, Heike Hunger, Sandra Schwarz, Manit Srisurapanont, Werner Kissling, Stefan Leucht

Cochrane Database of Systematic Reviews, CD006625 · Published 18 January 2010 · DOI 10.1002/14651858.cd006625.pub2

Open full textView at the publisherCite this paper

In brief

“Quetiapine versus other atypical antipsychotics for schizophrenia” is a 2010 journal article by Katja Komossa and 7 co-authors, published in Cochrane Database of Systematic Reviews. OpenAlex counts 268 citations as of 20 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
268
Most cited in
2016 (28)
References
364
Authors
8

Abstract

BACKGROUND: In many countries of the industrialised world second generation ('atypical') antipsychotic drugs have become the first line drug treatment for people with schizophrenia. It is not clear how the effects of the various second generation antipsychotic drugs differ. OBJECTIVES: To evaluate the effects of quetiapine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychosis. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group Trials Register (April 2007), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised control trials comparing oral quetiapine with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone or zotepine in people with schizophrenia or schizophrenia-like psychosis. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a random-effects model. MAIN RESULTS: The review currently includes 21 randomised control trials (RCTs) with 4101 participants. These trials provided data on four comparisons - quetiapine versus clozapine, olanzapine, risperidone or ziprasidone.A major limitation to all findings is the high number of participants leaving studies prematurely (57.6%) and the substantial risk of biases in studies. Efficacy data favoured olanzapine and risperidone compared with quetiapine (PANSS total score versus olanzapine:10 RCTs, n=1449, WMD 3.66 CI 1.93 to 5.39; versus risperidone: 9 RCTs, n=1953, WMD 3.09 CI 1.01 to 5.16), but clinical meaning is unclear. There were no clear mental state differences when quetiapine was compared with clozapine or ziprasidone.Compared with olanzapine, quetiapine produced slightly fewer movement disorders (6 RCTs, n=1090, RR use of antiparkinson medication 0.49 CI 0.3 to 0.79, NNH 25 CI 14 to 100) and less weight gain (7 RCTs, n=1173, WMD -2.81 CI -4.38 to -1.24) and glucose elevation, but more QTc prolongation (3 RCTs, n=643, WMD 4.81 CI 0.34 to 9.28). Compared with risperidone, quetiapine induced slightly fewer movement disorders (6 RCTs, n=1715, RR use of antiparkinson medication 0.5 CI 0.3 to 0.86, NNH 20 CI 10 to 100), less prolactin increase (6 RCTs, n=1731, WMD -35.28 CI -44.36 to -26.19) and some related adverse effects, but more cholesterol increase (5 RCTs, n=1433, WMD 8.61 CI 4.66 to 12.56). Compared with ziprasidone, quetiapine induced slightly fewer extrapyramidal adverse effects (1 RCT, n=522, RR use of antiparkinson medication 0.43 CI 0.2 to…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, CD006625. https://doi.org/10.1002/14651858.cd006625.pub2

MLA 9

Komossa, Katja, et al. “Quetiapine versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews, no. 1, 2010, p. CD006625. https://doi.org/10.1002/14651858.cd006625.pub2.

Chicago

Komossa, Katja, Christine Rummel‐Kluge, Franziska Schmid, Heike Hunger, Sandra Schwarz, Manit Srisurapanont, Werner Kissling, and Stefan Leucht. 2010. “Quetiapine versus other atypical antipsychotics for schizophrenia.” Cochrane Database of Systematic Reviews (1): CD006625. https://doi.org/10.1002/14651858.cd006625.pub2.

Harvard

Komossa, K. et al. (2010) ‘Quetiapine versus other atypical antipsychotics for schizophrenia’, Cochrane Database of Systematic Reviews, p. CD006625. doi:10.1002/14651858.cd006625.pub2.

IEEE

K. Komossa et al., “Quetiapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, p. CD006625, 2010, doi: 10.1002/14651858.cd006625.pub2.

BibTeX

@article{komossa2010quetiapine,
  title     = {{Quetiapine versus other atypical antipsychotics for schizophrenia}},
  author    = {Komossa, Katja and Rummel‐Kluge, Christine and Schmid, Franziska and Hunger, Heike and Schwarz, Sandra and Srisurapanont, Manit and Kissling, Werner and Leucht, Stefan},
  journal   = {Cochrane Database of Systematic Reviews},
  year      = {2010},
  number    = {1},
  pages     = {CD006625},
  doi       = {10.1002/14651858.cd006625.pub2},
  url       = {https://doi.org/10.1002/14651858.cd006625.pub2}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20162828
20171313
20181515
20191515
20201616
20211717
202288
202366
202466
202533

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • quetiapine
  • atypical antipsychotics
  • schizophrenia
  • schizophrenia-like psychosis
  • olanzapine
  • risperidone
  • clozapine
  • ziprasidone

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews, CD006625. https://doi.org/10.1002/14651858.cd006625.pub2

How many times has this paper been cited?

268 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Katja Komossa, Christine Rummel‐Kluge, Franziska Schmid, Heike Hunger, Sandra Schwarz, Manit Srisurapanont, Werner Kissling, Stefan Leucht.

What is the DOI of this paper?

10.1002/14651858.cd006625.pub2, permanently at https://doi.org/10.1002/14651858.cd006625.pub2. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.